Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

43.67 +0.58 (+1.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
18 19 Next >
Facebook Turns To Generative AI For Help, FedEx Consolidates, UBS Executives Say Surprise Credit Suisse Deal 'Major Challenge:' Today's Top Stories
Benzinga 
Via Benzinga
Farallon Capital Might Undertake Proxy Fight Against Exelixis, Nominates Three Directors
Via Benzinga
Farallon Issues Letter to Exelixis Board of Directors Outlining Case for Change
From Farallon Capital Management L.L.C.
Via Business Wire
2 Incredible Stocks to Buy With Less Than $25
Nothing beats a great investment for the price of just a few cups of coffee. 
Via The Motley Fool
Why Exelixis Stock Leaped More Than 4% Higher Today
Oh, how some investors love stock buyback programs. 
Via The Motley Fool
Analyst Ratings for Exelixis
Via Benzinga
2 Stocks to Buy With Less Than $20
Some relatively low-priced shares can be good buys, too. 
Via The Motley Fool
Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
In a welcome move, Exelixis stock saw its Relative Strength Rating improve to 73 on Monday, up from 69 a day earlier. 
Via Investor's Business Daily
Exelixis Announces $550 Million Share Repurchase Program
From Exelixis, Inc.
Via Business Wire
3 Beaten-Down Stocks That Could Soar This Year
These stocks could enjoy big rebounds in 2023. 
Via The Motley Fool
Exelixis Stock Generating Improved Relative Strength Rating
Exelixis stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 69 to 76. 
Via Investor's Business Daily
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
The Latest Analyst Ratings for Exelixis
Via Benzinga
Looking Into Exelixis's Return On Capital Employed
Via Benzinga
Exelixis (EXEL) Q4 2022 Earnings Call Transcript
EXEL earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
From Exelixis, Inc.
Via Business Wire
Nasdaq Bear Market: 5 Stunning Growth Stocks You'll Regret Not Buying on the Dip
A 33% plunge in the previously high-flying Nasdaq Composite is the perfect time for growth investors to pounce on some amazing deals. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
Via Benzinga
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
Via Benzinga
US Stocks Look To Snap String Of Weekly Losses As Futures Signal Positive Start Ahead Of Service Sector Data, Fed Speeches
U.S. stocks have returned to their cautious ways after their resilience performance on Thursday. The major index futures point to a modestly higher opening on Friday. Cues From Thursday’s Trading: 
Via Benzinga
Dell, Zscaler, Marvell Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip
A 33% plunge in the growth-dependent Nasdaq Composite is the perfect excuse for investors to buy into these innovative businesses. 
Via The Motley Fool
Bristol Myers Squibb-Exelixis Highlight Three-Year Follow Up Data From Opdivo+Cabometyx Combo Therapy In Kidney Cancer
Via Benzinga
2 Under-the-Radar Biotech Stocks to Buy in 2023
These stocks may soon start turning heads with their revenue growth. 
Via The Motley Fool
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb and Exelixis, Inc.
Via Business Wire
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These companies could grow in prominence in the coming years. 
Via The Motley Fool
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.